At the news
? BEARISHIMPACT 6/10 S-3 filed Nov 9, 2026 at 08:05 ET
Turn Therapeutics filed a universal shelf registration statement on Form S-3 to offer up to $150M in securities, including a $50M at-the-market (ATM) equity program with TD Cowen. The company is a pre-revenue clinical-stage biotech with a net loss of $6.2M in Q3 2026 and only $10.4M in cash, making this a capital raise to fund operations and clinical trials into Q3 2027. The filing signals significant potential dilution for existing shareholders.
- Shelf registration for up to $150M in securities, including a $50M ATM with TD Cowen.
- Company reported a net loss of $6.2M in Q3 2026, wider than $1.9M loss in Q3 2025.
- Cash and cash equivalents of $10.4M as of September 30, 2026, funding operations into Q3 2027.
- Pre-revenue clinical-stage biotech with no approved products.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access